E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma
Publication date
1979-12
Authors
Bramwell, V.H.C.
Brugarolas, A.
Mouridsen, H.T.
Cheix, F.
Jager, R. de
Oosterom, A.T. van
Vendrik, C.P.
Pinedo, H.M.
Sylvester, R.
Pauw, M. de
Editors
Advisors
Supervisors
DOI
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Cis-diamminodichloroplatinum (II) (cis-DDP), 100 mg/m2 every 3 weeks was administered to 24 patients with advanced soft tissue sarcoma. All patients had received extensive prior chemotherapy and had measurable progressive disease and normal renal function on entry to the study. There were no objective responses in the 17 patients receiving an adequate trial of therapy. Nausea and vomiting were universal. Renal impairment was moderate in 2 patients and mild in 4. Serial audiometry detected hearing loss at high frequencies in 3 patients.